Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
399 active trials17 approved drugs64 evidence items
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00227760 | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01014065 | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)(SUPER) | completed | — | 42 | AHS Cancer Control AlbertaOTHER |
| 1 |
| Feb 25, 2016 |
| clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01390519 | A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor(OSAT) | completed | — | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00531544 | A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | completed | N/A | 350 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT00480389 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | completed | Phase 2 | 19 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT00694096 | Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response | completed | Phase 1 | 25 | University of UtahOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT01122615 | Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01227213 | The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma | completed | — | 20 | Radboud University Medical CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT01525017 | A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | MendusINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00842790 | Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging(REMISCAN) | completed | — | 107 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01548482 | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01012011 | Regulatory Post Marketing Surveillance Study on Nexavar® | completed | — | 2,845 | BayerINDUSTRY | 1 | Sep 21, 2015 | clinicaltrials |
| NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | completed | Phase 2 | 14 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT01997788 | The Intrathecal Morphine for Nephrectomy(EMPON) | completed | N/A | 46 | Seoul National University HospitalOTHER | 1 | Jul 3, 2015 | clinicaltrials |
| NCT00126490 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00854620 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02030717 | Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma(ASA) | completed | Phase 2 / Phase 3 | 120 | Umeå UniversityOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00083109 | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00743054 | microRNA Expression in Renal Cell Carcinoma | completed | — | 50 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2015 | clinicaltrials |
| NCT00731211 | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT01827254 | Sutent Rechallenge In mRCC Patients(RESUME) | completed | — | 61 | PfizerINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00422019 | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 61 | AmgenINDUSTRY | 0 | Apr 10, 2015 | clinicaltrials |
| NCT01446224 | Cardiovascular and Torsades de Pointes Monitoring for Pazopanib | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Mar 27, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00788060 | A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma(Rad/Sutent) | completed | Phase 1 | 5 | Daniel George, MDOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01508364 | Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma(NEXTAR) | completed | — | 20 | BayerINDUSTRY | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00126503 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00661375 | BAY43-9006 Phase II Study for Renal Cell Carcinoma | completed | Phase 2 | 131 | BayerINDUSTRY | 1 | Dec 25, 2014 | clinicaltrials |
| NCT01034878 | Sunitinib in Metastatic Renal Cancer | completed | Phase 2 | 25 | Istituto Clinico HumanitasOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00044564 | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 54 | BayerINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | completed | Phase 2 | 501 | BayerINDUSTRY | 2 | Dec 19, 2014 | clinicaltrials |
| NCT01015911 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | completed | Phase 1 | 58 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00520403 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | completed | Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Oct 13, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 29, 2016source: clinicaltrials